- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN Updates Guidelines for Hereditary Colon Cancer Testing
The National Comprehensive Cancer Network (NCCN) has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults.
Myriad Genetics, Inc. is pleased to note that the National Comprehensive Cancer Network (NCCN) has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults.
Myriad believes the new guidelines will dramatically expand the number of patients eligible for hereditary colon cancer testing, especially among at-risk asymptomatic patients for whom screening has historically been limited based upon prior guidelines and a lack of insurance reimbursement. Some of the key aspects of the new guidelines include:
- A recommendation that all patients who meet a five percent or greater risk threshold for Lynch syndrome are appropriate for testing;
- A recommendation against sequential testing for the five Lynch syndrome genes in lieu of panel testing; and
- An acknowledgement that patients with cancer can proceed directly to sequencing tests without a complicated tissue screening algorithm.
Read the full story here: http://bit.ly/1f3tyki
Source: Myriad
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
